Q2 2024 ZimVie Inc Earnings Call Transcript
Key Points
- ZimVie Inc (ZIMV) achieved a revenue of $117 million in Q2 2024, showcasing strong execution and innovation across its portfolio.
- The company launched new dental implant products, TSX and T3 PRO, and gained FDA clearance for GenTek Restorative Components in the U.S., expanding its prosthetic offerings.
- ZimVie Inc (ZIMV) reported over 20% growth in its Implant Concierge service and surgical guide sales with RealGUIDE software, enhancing efficiency and safety in dental procedures.
- The company formed a new scanner partnership with Medit, expanding its digital solutions suite and offering a broader range of scanner price points.
- ZimVie Inc (ZIMV) reaffirmed its full-year revenue guidance of $450 million to $460 million and remains committed to achieving a 15% plus EBITDA margin by April 2025.
- Total third-party net sales for Q2 2024 decreased by 1.5% in reported rates and 0.4% in constant currency, indicating a slight decline in sales performance.
- U.S. implant sales were weaker, and there was pressure on capital sales, particularly oral scanners, impacting overall sales growth.
- The company expects Q3 2024 revenue to be sequentially lower and down 3% to 4% year-over-year due to seasonal impacts and market challenges.
- ZimVie Inc (ZIMV) experienced a decline in sales outside the U.S. by 3.8% on a reported basis and 1.2% in constant currency, reflecting international market pressures.
- The company faces ongoing challenges in the dental market, with underlying market issues not fully subsided, necessitating a prudent approach to future quarters.
Good afternoon and welcome to ZimVie's Second Quarter 2024 earnings conference call. (Operator Instructions) As a reminder, this call is being recorded for replay purposes.
I would now like to turn the call over to Marissa Bych from Gilmartin Group for introductory disclosures.
Thank you all for joining today's call. Earlier today, ZimVie released financial results for the quarter ended June 30, 2024. A copy of the press release is available on the company's website, zimvie.com, as well as on sec.gov.
Before we begin, I'd like to remind you that management will make comments during this call that include forward-looking statements. Actual results may differ materially from those indicated by the forward-looking statements due to a variety of risks and uncertainties. Please refer to the company's most recent periodic report filed with the SEC and subsequent SEC filings for a detailed discussion of these risks and uncertainties.
In addition, the discussion on this call will include certain
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
